NIH #5UG1CA189863-11
Metro-Minnesota Community Oncology Research Consortium (MMCORC)
- Amount
- $3.9M
- Period
- 2014-08-01 → 2025-07-31
- PIs
- 3
- Est. capacity / PI
- ~0 students
Awarded at HEALTHPARTNERS INSTITUTE
Statistical Methods in Clinical Trials · Statistics and Probability
2 total · 0 active
NIH #5UG1CA189863-11
Awarded at HEALTHPARTNERS INSTITUTE
NIH #5UG1CA189863-10
Awarded at HEALTHPARTNERS INSTITUTE
Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.
Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.
Blood · 2025-11-03
The Lancet · 2025-10-19 · 38 citations
Identification and optimization of recurrent congestion driven by multisource data on highway
2025-09-29
European Journal of Cancer · 2025-09-23 · 9 citations
The generalized 3+3 (G3) design for Phase I trials: A design for clinicians
Contemporary Clinical Trials · 2025-09-13
Monitoring Adverse Events Through Bayesian Nonparametric Clustering Across StudiesPreprint
ArXiv.org · 2025-09-08
Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology DataPreprint
ArXiv.org · 2025-09-05
API behavior monitoring based on Nginx reverse proxy
2025-05-23 · 2 citations
ArXiv.org · 2025-05-19
2025-04-07
The Annals of Applied Statistics · 2025-03-01
The modified combo i3 + 3 design for novel-novel combination dose-finding trials in oncology
Contemporary Clinical Trials · 2025-02-21
2025-02-13
Circulating molecules reflect imaging biomarkers of hemorrhage in cerebral cavernous malformations
Journal of Cerebral Blood Flow & Metabolism · 2025-01-20 · 4 citations
The Generalized 3+3 (G3) Design for Phase I Trials: A Design for CliniciansPreprint
SSRN Electronic Journal · 2025-01-01
Journal of Contemporary Educational Research · 2024-12-30
Changes and Challenges of Graduate Education in the Era of Education Digitalization
Journal of Contemporary Educational Research · 2024-11-27 · 2 citations
The Generalized 3+3 (G3+3) Design for Phase I Dose-Finding TrialsPreprint
medRxiv · 2024-08-19